BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 20, 2026
Home » Authors » Douglas Merrill

Articles by Douglas Merrill

Mtm, EMBLEM Collaborate In Bioinformatics, Cancer

Oct. 9, 2002
By Douglas Merrill

GLSV Launches EUR143M Fund, Seeks Strong Biotech Leaders

Oct. 9, 2002
By Douglas Merrill
MUNICH, Germany - Global Life Science Ventures GmbH raised €143 million for a new fund that will invest in private biotechnology companies in Europe and the U.S. (Bioworld International
Read More

Xerion Raises EUR12.3M To Develop Antibody, Cardiovascular Pipeline

Oct. 9, 2002
By Douglas Merrill

Mtm, EMBLEM Collaborate In Bioinformatics, Cancer

Oct. 9, 2002
By Douglas Merrill

GLSV Launches EUR143M Fund, Seeks Strong Biotech Leaders

Oct. 9, 2002
By Douglas Merrill
MUNICH, Germany - Global Life Science Ventures GmbH raised €143 million for a new fund that will invest in private biotechnology companies in Europe and the U.S. (Bioworld International
Read More

Xerion Raises EUR12.3M To Develop Antibody, Cardiovascular Pipeline

Oct. 9, 2002
By Douglas Merrill

Improving Processes Key For Helping Companies Raise Profits

Oct. 2, 2002
By Douglas Merrill

Germany Closing Neuer Markt Amid Mounting Losses, Scandals

Oct. 2, 2002
By Douglas Merrill
MUNICH, Germany - Deutsche Boerse AG, the company that operates Germany's most important stock markets, is closing the Neuer Markt as part of a larger restructuring in the company's exchanges. The market was launched in March 1997 to expand the opportunities for high-growth, high-technology companies to raise capital in public markets. (BioWorld International)
Read More

Germany Closing Neuer Markt Amid Mounting Losses, Scandals

Oct. 2, 2002
By Douglas Merrill
MUNICH, Germany - Deutsche Boerse AG, the company that operates Germany's most important stock markets, is closing the Neuer Markt as part of a larger restructuring in the company's exchanges. The market was launched in March 1997 to expand the opportunities for high-growth, high-technology companies to raise capital in public markets. (BioWorld International)
Read More

Improving Processes Key For Helping Companies Raise Profits

Oct. 2, 2002
By Douglas Merrill
Previous 1 2 … 18 19 20 21 22 23 24 25 26 27 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 20, 2026.
  • ALN-5288 lowers tau levels in preclinical models

    BioWorld Science
    Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
  • Elderly hands holding broken brain structure

    Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

    BioWorld Science
    Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
  • International currency symbols

    Capital remains selective in ‘barbell’ biotech market

    BioWorld
    Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
  • Brush scrubbing brain figurine with soap

    PSB-229 reduces plaque burden in Alzheimer’s models

    BioWorld Science
    Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing